The lifetime prevalence and impact of generalized anxiety disorders in an epidemiologic Italian National Survey carried out by clinicians by means of semi-structured interviews.
Community survey
Comorbidity
Epidemiology
Generalized anxiety disorder
Quality of life
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
20 01 2021
20 01 2021
Historique:
received:
27
06
2020
accepted:
05
01
2021
entrez:
21
1
2021
pubmed:
22
1
2021
medline:
27
4
2021
Statut:
epublish
Résumé
Generalized anxiety disorder (GAD) is one of the most reported diagnoses in psychiatry, but there is some discrepancy between the cases identified in community studies and those identified in tertiary care. This study set out to evaluate whether the use of clinicians as interviewers may provide estimates in a community survey close to those observed in primary or specialized care. This is a community survey on a randomly selected sample of 2338 adult subjects. The Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS) was administered by clinicians, providing lifetime diagnosis based on the DSM-IV-TR. Health-related quality of life (HR-QoL) was measured with the Short-Form Health Survey (SF-12). Overall, 55 (2.3%) subjects met the criteria for GAD, with greater prevalence in women (3.6%) than in men (0.9%): OR = 4.02; 95%CI: 1.96-8.26. Up to 40% of those with GAD had at least another diagnosis of mood, anxiety, or eating disorders. The mean score of SF-12 in people with GAD was 32.33 ± 6.8, with a higher attributable burden than in other conditions except for major depressive disorder. We found a relatively lower lifetime prevalence of GAD than in community surveys based on lay interviewers and a structured interview. The identified cases of GAD showed a strong impact on the quality of life regardless of co-morbidity and high risk in women, suggesting a profile similar to the one identified from studies in primary and specialized care.
Sections du résumé
BACKGROUND
Generalized anxiety disorder (GAD) is one of the most reported diagnoses in psychiatry, but there is some discrepancy between the cases identified in community studies and those identified in tertiary care. This study set out to evaluate whether the use of clinicians as interviewers may provide estimates in a community survey close to those observed in primary or specialized care.
METHODS
This is a community survey on a randomly selected sample of 2338 adult subjects. The Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS) was administered by clinicians, providing lifetime diagnosis based on the DSM-IV-TR. Health-related quality of life (HR-QoL) was measured with the Short-Form Health Survey (SF-12).
RESULTS
Overall, 55 (2.3%) subjects met the criteria for GAD, with greater prevalence in women (3.6%) than in men (0.9%): OR = 4.02; 95%CI: 1.96-8.26. Up to 40% of those with GAD had at least another diagnosis of mood, anxiety, or eating disorders. The mean score of SF-12 in people with GAD was 32.33 ± 6.8, with a higher attributable burden than in other conditions except for major depressive disorder.
CONCLUSIONS
We found a relatively lower lifetime prevalence of GAD than in community surveys based on lay interviewers and a structured interview. The identified cases of GAD showed a strong impact on the quality of life regardless of co-morbidity and high risk in women, suggesting a profile similar to the one identified from studies in primary and specialized care.
Identifiants
pubmed: 33472585
doi: 10.1186/s12888-021-03042-3
pii: 10.1186/s12888-021-03042-3
pmc: PMC7816458
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Subventions
Organisme : Agenzia Italiana del Farmaco, Ministero della Salute
ID : FARM54S73S
Références
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Psychiatry Res. 2010 Apr 30;176(2-3):197-201
pubmed: 20129676
Transl Psychiatry. 2015 Mar 31;5:e536
pubmed: 25826111
Pharmacoeconomics. 2020 Jan;38(1):25-37
pubmed: 31646432
Acta Psychiatr Scand Suppl. 2004;(420):21-7
pubmed: 15128384
Brain Behav. 2019 Jun;9(6):e01284
pubmed: 31066227
Psychiatry Res. 2011 Feb 28;185(3):444-9
pubmed: 20656360
Presse Med. 2017 Dec;46(12 Pt 1):1124-1138
pubmed: 29150233
J Nerv Ment Dis. 2007 Mar;195(3):203-10
pubmed: 17468679
Curr Psychiatry Rep. 2016 Mar;18(3):23
pubmed: 26830881
BMC Psychiatry. 2011 Oct 10;11:164
pubmed: 21985128
Evid Based Ment Health. 2016 Aug;19(3):73-81
pubmed: 27405742
Dialogues Clin Neurosci. 2015 Sep;17(3):327-35
pubmed: 26487813
Acta Psychiatr Scand. 1989 Feb;79(2):136-47
pubmed: 2923007
Health Qual Life Outcomes. 2019 Apr 23;17(1):70
pubmed: 31014327
Br J Psychiatry. 1980 Oct;137:324-31
pubmed: 7448471
J Clin Psychiatry. 2003 Jan;64(1):53-9
pubmed: 12590624
Clin Pract Epidemiol Ment Health. 2019 Feb 20;15:30-37
pubmed: 30972140
Am J Prev Med. 2019 Oct;57(4):545-556
pubmed: 31542132
J Anxiety Disord. 2015 Jan;29:1-6
pubmed: 25465882
J Affect Disord. 2015 Feb 1;172:24-9
pubmed: 25451391
Expert Opin Pharmacother. 2018 Jun;19(8):883-894
pubmed: 29806492
Compr Psychiatry. 2012 Nov;53(8):1056-62
pubmed: 22578985
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Int J Soc Psychiatry. 2015 Nov;61(7):693-9
pubmed: 25770204
Psychother Psychosom. 2004 Jul-Aug;73(4):216-25
pubmed: 15184716
Braz J Psychiatry. 2019 Jul-Aug;41(4):336-362
pubmed: 31116259
Am J Geriatr Psychiatry. 2009 Jun;17(6):473-82
pubmed: 19472438
Support Care Cancer. 1996 Mar;4(2):129-40
pubmed: 8673350
J Anxiety Disord. 2019 Aug;66:102106
pubmed: 31252250
Front Psychiatry. 2020 Mar 31;11:188
pubmed: 32296351
Arch Gen Psychiatry. 1994 Jan;51(1):8-19
pubmed: 8279933
Neuroimage Clin. 2019;24:102016
pubmed: 31835287
Clin Pract Epidemiol Ment Health. 2019 Feb 28;15:38-43
pubmed: 30972141
Am J Psychiatry. 2003 Jan;160(1):4-12
pubmed: 12505793
Public Health Rep. 1992 Nov-Dec;107(6):663-8
pubmed: 1454978
Int J Geriatr Psychiatry. 1998 Oct;13(10):717-26
pubmed: 9818308
Epidemiol Psichiatr Soc. 2007 Apr-Jun;16(2):144-51
pubmed: 17619546
Clin Pract Epidemiol Ment Health. 2010 Aug 27;6:94-100
pubmed: 21253459
JAMA Psychiatry. 2020 Mar 1;77(3):265-273
pubmed: 31758858
JAMA Psychiatry. 2017 May 1;74(5):465-475
pubmed: 28297020
J Psychosom Res. 2016 Nov;90:51-56
pubmed: 27772559
Depress Anxiety. 2002;16(4):162-71
pubmed: 12497648
World Psychiatry. 2010 Jun;9(2):103-10
pubmed: 20671899
Clin Pract Epidemiol Ment Health. 2005 Jul 21;1:8
pubmed: 16042762
Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84
pubmed: 22865617
Int Rev Psychiatry. 2014 Aug;26(4):486-92
pubmed: 25137115
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:31-38
pubmed: 30876986